105686-91-7

Basic information

• Product Name: 1-(4-METHOXYPHENYL)-3-(3,4,5-TRIMETHOXYPHENYL)PROP-2-EN-1-ONE
• Synonyms: 1-(4-METHOXYPHENYL)-3-(3,4,5-TRIMETHOXYPHENYL)PROP-2-EN-1-ONE
• CAS NO: 105686-91-7
• Molecular Formula: C₁₉H₂₀O₅
• Molecular Weight: 328.36
• Mol File: 105686-91-7.mol
• Article Data: 16

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(4-METHOXYPHENYL)-3-(3,4,5-TRIMETHOXYPHENYL)PROP-2-EN-1-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-METHOXYPHENYL)-3-(3,4,5-TRIMETHOXYPHENYL)PROP-2-EN-1-ONE(105686-91-7)
• EPA Substance Registry System: 1-(4-METHOXYPHENYL)-3-(3,4,5-TRIMETHOXYPHENYL)PROP-2-EN-1-ONE(105686-91-7)

Safety Data

• Hazardous Substances Data: 105686-91-7(Hazardous Substances Data)

Usage

General Description

The chemical 1-(4-Methoxyphenyl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one is a compound with a complex structure consisting of a propenone backbone with two phenyl rings attached. The compound is classified as a chalcone, a type of molecule often found in plants and known for its antioxidant and anti-inflammatory properties. The presence of methoxy and trimethoxy groups on the phenyl rings indicates that this compound may have potential medicinal or biological activity due to the presence of natural compounds such as flavonoids and phenolic compounds. This chemical structure has the potential to be used in pharmaceutical and medicinal research for the development of new drugs or biologically active compounds.

Upstream product

• 86-81-7 3,4,5-trimethoxy-benzaldehyde 
• 100-06-1 1-(4-methoxyphenyl)ethanone 
• 1136-86-3 methyl (3,4,5-trimethoxyphenyl) ketone 
• 123-11-5 4-methoxy-benzaldehyde 

Downstream Products

• 105686-83-7 2-(4-Chloro-phenyl)-6-(4-methoxy-phenyl)-4-(3,4,5-trimethoxy-phenyl)-pyridine 
• 105686-79-1 2-(4-Methoxy-phenyl)-6-phenyl-4-(3,4,5-trimethoxy-phenyl)-pyridine 
• 105686-87-1 2-(4-Methoxy-phenyl)-6-p-tolyl-4-(3,4,5-trimethoxy-phenyl)-pyridine 
• 56177-96-9 3-(4-methoxyphenyl)-1-(3,4,5-trimethoxyphenyl)propane 
• 110047-50-2 1-(4-methoxyphenyl)-3-(3,4,5-trimethoxyphenyl)propan-1-one 

Relevant articles and documents

Synthesis and antimitotic properties of ortho-substituted polymethoxydiarylazolopyrimidines

Ortho-substituted polymethoxydiarylazolopyrimidines were synthesized using polymethoxysubstituted benzaldehydes and acetophenones as starting material. X-ray crystallography data clearly confirmed that the subsequent cyclization of 3-amino-1,2,4-triazole

The influence of methoxy and ethoxy groups on supramolecular arrangement of two methoxy-chalcones

The structures of two methoxylated chalcones, namely (E)-1-(4-methoxyphenyl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one and (E)-3-(4-ethoxyphenyl)-1-(4-methoxyphenyl) prop-2-en-1-one, reveal the effect of the inclusion of the methoxyl and ethoxyl substitue

A novel series of benzothiazepine derivatives as tubulin polymerization inhibitors with anti-tumor potency

In this work, a series of diaryl benzo[b][1,4]thiazepine derivatives D1-D36 were synthesized and screened as tubulin polymerization inhibitors with anti-tumor potency. They were designed by introducing the seven-member ring benzothiazepine as the linker f

The synthesis of chalcones as anticancer prodrugs and their bioactivation in CYP1 expressing breast cancer cells

Background: Although the expression levels of many P450s differ between tumour and corresponding normal tissue, CYP1B1 is one of the few CYP subfamilies which is significantly and consistently overexpressed in tumours. CYP1B1 has been shown to be active within tumours and is capable of metabolising a structurally diverse range of anticancer drugs. Because of this, and its role in the activation of procarcinogens, CYP1B1 is seen as an important target for anticancer drug development. Objective: To synthesise a series of chalcone derivatives based on the chemopreventative agent DMU-135 and investigate their antiproliferative activities in human breast cancer cell lines which express CYP1B1 and CYP1A1. Method: A series of chalcones were synthesised in yields of 43-94% using the Claisen-Schmidt condensation reaction. These were screened using a MTT assay against a panel of breast cancer cell lines which have been characterised for CYP1 expression. Result: A number of derivatives showed promising antiproliferative activities in human breast cancer cell lines which express CYP1B1 and CYP1A1, while showing significantly lower toxicity towards a non-tumour breast cell line with no CYP expression. Experiments using the CYP1 inhibitors acacetin and α-naphthoflavone provided supporting evidence for the involvement of CYP1 enzymes in the bioactivation of these compounds. Conclusion: Chalcones show promise as anticancer agents with evidence suggesting that CYP1 activation of these compounds may be involved.